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CLINICAL PRESENTATION
Endometrial cancer is rare in premenopausal women, usually
presenting with postmenopausal bleeding. This alarming symptom
prompts most affected women to present to their general
practitioner, which results in urgent referral to a gynaecological
unit. In premenopausal women, the usual menstrual pattern may
be disturbed, but irregular bleeding is common in the fifth decade
and referral may not be so prompt. If bleeding as an early sign is
disregarded, the tumour will progress; enlargement and spread to
the pelvic sidewall can result in pain.
DIAGNOSIS AND TREATMENT
The mainstay of diagnosis is a biopsy, obtained usually as an
outpatient under direct hysteroscopic vision or using a suction
instrument, such as a Pipelle, inserted through the cervical os. As
only around 8–10% of women who experience postmenopausal
bleeding actually have cancer, it is currently recommended that
women be screened initially with ultrasound of the uterus, which
clearly demonstrates the thickness of the endometrium. It has been
determined from a number of large studies that endometrial tissue
measuring less than 5mm thickness, has a negative predictive
value of 99%, thus avoiding the need for routine biopsy. The
current standard is to establish a ‘one-step’ rapid access clinic,
which combines clinical evaluation, ultrasound, and if necessary,
an endometrial biopsy with or without hysteroscopic exploration
of the endometrial cavity.
Complete assessment of an endometrial cancer requires the
histotype to be determined; although most are endometrioid, rarer
types such as clear-cell, papillary serous and carcinosarcoma, each
of which account for around 2–4% of the total, have a significantly
worse prognosis because of a more frequent rate of metastases at
presentation and a higher recurrence rate.
Treatment has not changed a great deal over the past 30 years,
although a number of clinical trials are beginning to inform
management in a more rational way. For early-stage disease, which
accounts for 80–90% of cases, management has relied on
hysterectomy and bilateral salpingo-oophorectomy followed by
pelvic radiotherapy if the tumour histology indicated a high-grade
tumour and/or deep myometrial invasion. Although pelvic radio-
therapy reduces the risk of local relapse, there is no evidence that it
affects overall survival and increasingly, systematic therapy
(chemotherapy) is being evaluated for high-risk or metastatic
disease.
INTERPRETATION OF SURVIVAL PATTERNS
The incidence of endometrial cancer has risen in the United
Kingdom as a result of increasing rates of obesity, increased life
expectancy and the use of tamoxifen as an adjuvant therapy for
breast cancer. Disease occurring as a result of obesity and
tamoxifen is generally detected at an early stage and often is well
differentiated leading to high disease-specific survival. Enhanced
heath awareness and rapid systems of referral and diagnosis may
also be implicated in the slightly higher proportion of early-stage
disease. In addition, there may have been some disease shift as a
result of the increased practice of lymphadenectomy to stage the
disease. This means that disease classified as stage I is more likely
to be truly confined to the uterine corpus than disease only defined
by hysterectomy and bilateral salpingo-oophorectomy, in which a
small proportion will have occult node involvement, and should be
classified as stage 3.
It may be that the small increase in survival over the past 10–15
years is due to a combination of these factors, and to optimal
treatment in a higher proportion of cases, as more women are
treated by specialist teams.
DEPRIVATION GAP
The small but real difference in survival according to the
deprivation index may be best explained by comorbidity. Women
with endometrial cancer have relatively high rates of obesity,
hypertension, coronary artery disease, diabetes and chronic
respiratory disease. This complex of comorbidity is likely to be
more common among women living in deprived areas. A
significant proportion of deaths within 5 years of endometrial
cancer being diagnosed is due to other causes but may include
endometrial cancer on the death certificate. It is possible that
deprivation is associated with delayed diagnosis but this is a less
likely explanation. Gross obesity, which is increasingly common
may not only be the cause of the disease but can preclude curative
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CLOSING THE DEPRIVATION GAP
There is no reason why deprivation should now have a detrimental
effect on the quality of cancer care for endometrial cancer. The means
of closing the deprivation gap may lie in a general improvement in
health indices so that women who are cured of endometrial cancer
have a high prospect of prolonged survivorship. Reduction in obesity
and smoking will be major factors in achieving this.
OVERALL COMMENT
Although survival in endometrial cancer is higher than many
other cancers including the other gynaecological cancers there is a
need to save more lives. This may be achievable by changes
in lifestyle (especially obesity) but in the absence of a secondary
prevention strategy there needs to be improvement in the
treatment of advanced disease, which is currently difficult to cure.
We will see more trials of chemotherapy both cytotoxic and
biological agents, for example, antiangiogenic agents, over the next
10 years, which will demonstrate whether greater cure rates are
possible.
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